Orphan Technologies to be acquired by Retrophin for up to USD 517m 

Retrophin, a San Diego, California-based biopharmaceutical company, will acquire Orphan Technologies Limited, a Swiss clinical-stage biopharmaceutical company, for up to USD 517m.

Cooley acted as legal counsel to Retrophin. Barclays acted as financial advisor.

Hogan Lovells US acted as legal counsel to Orphan Technologies and Cantor Fitzgerald & Co. acted as financial advisor.